EVOLUTION-HF DEallEF: A Non-Interventional Study of Patients with Heart Failure Initiated On Dapagliflozin: Study Design
EVOLUTION-HF DE<sub>allEF</sub> will deliver relevant insights into real-world dapagliflozin treatment for HF focusing on clinical and patient perspective in Germany.
Authors
- Sarah Riemann (ORCID: https://orcid.org/0000-0003-0760-9794)
- Birgit Aßmus (ORCID: https://orcid.org/0000-0003-2658-6444)
- Angelika Guth
- Ralph Bosch
- Behrus Subin
- Matthias Paul (ORCID: https://orcid.org/0000-0003-4369-1270)
- Marlena Mueller
- Mareike Seelinger
Institutions
- German Society of Surgery (DE)
- Justus-Liebig-Universität Gießen (DE)
- University of Münster (DE)
- Ludwigsburg University of Education (DE)
- University Hospital Münster (DE)
- AstraZeneca (France) (FR)
- Promentis Pharmaceuticals (United States) (US)
- German Centre for Cardiovascular Research (DE)
- Kerckhoff Klinik (DE)
- Hamburg Institut (Germany) (DE)
- Klinikum Ludwigsburg (DE)
- Giessen School of Theology (DE)
- AstraZeneca (Germany) (DE)
- FH Münster University of Applied Sciences (DE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/ehf2.15312
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca